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Therapy of Canine Hyperlipidemia with Bezafibrate
V. De Marco, K.S.M. Noronha, T.C. Casado, E.R. Nakandakare, J.C. Florio, E.Z. Santos, and
C. Gilor
Background: Bezafibrate (BZF) is effective in the treatment of hypertriglyceridemia in human patients, but there are no
data on its use in dogs.
Objective: To assess the safety of BZF in hyperlipidemic dogs and its efficacy in decreasing serum triglyceride (TG) and
cholesterol (CHO) concentrations.
Animals: Forty-six dogs, 26 females and 20 males, mean (SD) age of 9 (3) years, with TG ≥150 mg/dL (33 dogs also
were hypercholesterolemic [>300 mg/dL]).
Methods: Prospective, uncontrolled clinical trial. Dogs were treated with bezafibrate once daily, using 200 mg tablets at a
dosage of 4–10 mg/kg (depending on body weight). Serum TG and CHO concentrations and alanine aminotransferase (ALT)
and creatine kinase (CK) activity before and after 30 days of treatment were compared.
Results: Sixteen dogs (34.8%) had primary hyperlipidemia, and 30 dogs (65.2%) had secondary hyperlipidemia (including
spontaneous hyperadrenocorticism [41.3%, n = 19/46], chronic treatment with glucocorticoids [10.8%, n = 5/46], and
hypothyroidism [15.2%, n = 7/46]). After 30 days, serum TG concentration normalized (<150 mg/dL) in 42 dogs (91.3%)
and CHO concentration normalized (<270 mg/dL) in 22 of 33 dogs (66.7%). There was no difference in baseline TG concen-
tration between the primary and secondary hyperlipidemia subgroups, but the decrease in TG concentration after treatment
was greater in the primary hyperlipidemia subgroup. No adverse effects were observed, but ALT activity decreased signifi-
cantly after 30 days of treatment.
Conclusions and Clinical Importance: Over 30 days, BZF was safe and effective in treatment of primary and secondary
hyperlipidemia in dogs.
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Hyperlipidemia (or dyslipidemia) is defined as anincrease in serum triglyceride (TG) concentration
(hypertriglyceridemia) or serum cholesterol (CHO)
concentration (hypercholesterolemia) or both.1,2 Hyper-
lipidemia is common in dogs, and it can be present as a
primary or secondary condition. Secondary hyperlipi-
demia is more common and can be caused by endocrine
disorders (e.g, hypothyroidism, hyperadrenocorticism,
diabetes mellitus) and less commonly by obesity, pan-
creatitis, protein-losing nephropathy, hepatic cholesta-
sis, high fat feeding, and therapy with corticosteroids.3–6
Primary hyperlipidemia usually is a familial or heredi-
tary disorder of lipoprotein metabolism.1,2,7 It has been
reported in Miniature Schnauzers, Shetland sheepdogs,
Beagles, and other breeds.8–10 The etiology of primary
hyperlipidemia is not well understood. Based on the
various phenotypes in different breeds, there is likely >1
etiology. Primary hyperlipidemia might be caused by
genetic defects in lipoprotein lipase or absence of
apoprotein IIC, but mutations in these genes have not
yet been identified in dogs.2,11,12
Hyperlipidemia is a challenging disease because most
hyperlipidemic dogs are asymptomatic. Two studies
investigated primary hyperlipidemia in seemingly
healthy Schnauzers and found that the frequency of
hyperlipidemia was 32.8% and 56.4%.8,a Therefore,
predisposed breeds and dogs with endocrinopathies
should be regularly screened for early recognition of
this metabolic disorder.
Hyperlipidemia in dogs has been associated with sev-
eral clinical complications such as pancreatitis, insulin
resistance, increased liver enzyme activities, gall bladder
mucocele, seizures, behavioral changes, peripheral neu-
ropathies, and ocular abnormalities.13–19 Hyperlipi-
demia can be the cause of atherosclerotic disease and
endothelial lesions that can lead to cardiovascular dys-
function and affect other organs such as the brain and
kidney.20,21 Because of these potential complications,
there is a need for effective therapy to decrease or nor-
malize of the serum TG and CHO concentrations.
From the University of Santo Amaro, S~ao Paulo, Brazil (De
Marco, Santos); University of Guarulhos, S~ao Paulo, Brazil (De
Marco, Noronha, Casado); Medicine School, University of S~ao
Paulo, S~ao Paulo, Brazil (Nakandakare); Veterinary Medicine
School, University of S~ao Paulo, S~ao Paulo, Brazil (Florio);
University of California, Davis, CA (Gilor).
Where the work was done: Veterinary Hospital of University of
Guarulhos.
Study support: none.
Meeting presentations: 2013 ACVIM Forum, Seattle, WA.
Corresponding author: C. Gilor, University of California, Davis.
1 Shields Ave, Davis, CA 95616; e-mail: cgilor@ucdavis.edu
Submitted December 12, 2016; Revised January 20, 2017;
Accepted February 23, 2017.
Copyright © 2017 The Authors. Journal of Veterinary Internal
Medicine published by Wiley Periodicals, Inc. on behalf of the Ameri-
can College of Veterinary Internal Medicine.
This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original
work is properly cited and is not used for commercial purposes.
DOI: 10.1111/jvim.14701
Abbreviations:
ALT alanine aminotransferase
BZF bezafibrate
CHO cholesterol
CK creatine kinase
PPAR peroxisome proliferator-activated receptor
TG triglyceride
VLDL very low density lipoproteins
Standard Article
J Vet Intern Med 2017;31:717–722
The initial approach to treatment of hyperlipidemia
consists of a low-fat diet and, in cases of secondary
hyperlipidemia, treatment of the underlying disease.
These treatment strategies, however, may be only par-
tially effective, and then, pharmacological intervention
should be considered.11,b The choice of a lipid-lowering
drug should be based on the underlying disturbance
causing the hyperlipidemia (e.g, excessive fat in the diet,
increased free fatty acid production in the liver,
increased lipid mobilization, and ineffective clearance of
lipids from the blood).11,22
Bezafibrate is a derivative of fibric acid that is used in
people as lipid-lowering drug. Fibrates are specifically
effective in treating hypertriglyceridemia. Mediated by
peroxisome proliferator-activated receptor (PPAR) a,
the effects of fibrates include induction of hepatic fatty
acid uptake and a decrease in hepatic triglyceride and
very low density lipoproteins (VLDL) synthesis,
increased activity of lipoprotein lipase, increased gall
bladder excretion of hepatic CHO, and increased
production of HDL. The combination of decreased
production with increased excretion results in
substantial lowering of circulating TG (in the form of
VLDL) concentration and a slight decrease in CHO
concentration.23,24 Common adverse effects of fibrate
therapy in people include muscle pain, emesis, diarrhea,
increased creatine kinase (CK) and alanine aminotrans-
ferase (ALT) activity, and predisposition to the forma-
tion of gallstones.24,25
Fibrates are the first drug of choice for treatment of
moderate-to-severe hyperlipidemia in people.23,25 In
dyslipidemic dogs, the therapeutic effects of fibrates
were reported only in isolated cases.c Therefore, the
objectives of our study were to investigate the therapeu-
tic efficacy of BZF in decreasing the serum concentra-
tions of TG and CHO and to assess possible adverse
effects within a 30-day treatment period.
Materials and Methods
Ours was a prospective study that included dogs that were
admitted to the Veterinary Service of University of Guarulhos,
Brazil. The study was approved by the University of Guarulhos
Bioethics committee. All dogs presented with hyperlipidemia
between January 2011 and December 2011 were considered for
inclusion. Dogs were included only if their primary disease status
was stable and if treatment of the primary disease could be post-
poned for 30 days (e.g, levothyroxine for hypothyroidism, trilos-
tane for hyperadrenocorticism). Similarly, dogs that were treated
with long-term glucocorticoid drugs for atopy were included if
their treatment regimen was stable and not expected to change
during the study. Dogs with increased CK or ALT activity (19
and 39, respectively, above the reference interval) were excluded
because of the risk of hepatotoxicity and rhabdomyolysis in
people.24
All blood tests were performed after at least 12 hours of fast-
ing. Dogs were included if they had a diagnosis of hyperlipidemia
based on increased TG or CHO concentrations above the labora-
tory’s reference interval (TG ≥150 mg/dL, CHO ≥300 mg/dL). Pri-
mary hyperlipidemia was diagnosed based on exclusion of diabetes
mellitus, hyperadrenocorticism, hypothyroidism, nephrotic syn-
drome, and therapy with glucocorticoid drugs or phenobarbital.
Tests for diagnosis and exclusion of these diseases were performed
at the discretion of the attending clinician based on clinical presen-
tation (including CBC, biochemistry panels, dexamethasone sup-
pression test [DST], serum total thyroxine concentrations [TT4],
thyroid-stimulating hormone [TSH] concentrations, and abdominal
ultrasonography).26
All dogs were treated with BZF once daily, immediately after
the main meal for 30 days. Because there are no standardized
dosages for BZF in the veterinary literature, and because BZF was
available only as 200 mg tablets, the dosage was extrapolated from
people and based on body weight category as described in
Table 1.
Serum concentrations of TG and CHO as well as ALT and CK
activity were measured before treatment and at the end of 30 days
of treatment.24 All biochemical tests were performed on an auto-
mated biochemistry analyzerc in the clinical pathology laboratory
at the School of Veterinary Medicine, Guarulhos University, S~ao
Paulo, Brazil. All hormone tests were performed in a reference
laboratory.d
Statistical analysis was performed using commercially available
computer software.e All variables were calculated for the group of
46 hyperlipidemic dogs and then separately for the 2 subgroups of
primary hyperlipidemia dogs and secondary hyperlipidemia dogs.
The change in TG, CHO, ALT, and CK from time zero (T0:
before initiation of treatment) to time 30 (T30: 30 days after initia-
tion of treatment) was defined as ΔTG, ΔCHO, ΔALT, and ΔCK,
respectively. Data are reported as mean  SD, and median
(range). Data were assessed for normal distribution using the
Shapiro–Wilk test. All data were not normally distributed, and
therefore, all comparisons were performed with nonparametric
tests. The Wilcoxon matched-pairs signed rank test was used to
compare the change from before and after treatment. The Mann-
Whitney U-test (nonpaired) was used to compare groups of dogs
with primary vs. secondary hyperlipidemia. Significance level was
set at P < .05.
Results
Forty-six dogs were included (26 female and 20
males) with a mean (SD) age of 9  3 years. Most
dogs were purebred including Miniature Schnauzer
(n = 11), Poodle (n = 8), Cocker Spaniel (n = 4),
Dachshund (n = 4), Yorkshire Terrier (n = 3), Shetland
Sheepdog (n = 2), Beagle (n = 2), Maltese (n = 2), 1
Bichon Frise (n = 1), Lhasa Apso (n = 1), Rottweiler
(n = 1), and Labrador Retriever (n = 1). Sixteen dogs
(34.8%) were diagnosed with primary hyperlipidemia
(all Miniature Schnauzers and Shetland Sheepdogs and
3 Cocker Spaniels) and 30 (65.2%) with secondary
hyperlipidemia (hyperadrenocorticism, n = 19/46
[41.3%]; hypothyroidism, n = 7/46 [15.2%], long-term
treatment with glucocorticoid drugs, n = 5/46 [10.8%]).
No diabetic dogs were included. All dogs with hypothy-
roidism or hyperadrenocorticism were newly diagnosed
Table 1. Dosing regimen of bezafibrate based on body
weight.
Body Weight
Bezafibrate 200 mg tablet, once daily
Dose in mg Tablet scoring
≤12 kg 50 ¼
12.1–25 kg 100 ½
>25 kg 200 1
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at the time of inclusion and were not treated for their
underlying disease during the 30 days of the study. All
46 dogs (100%) were hypertriglyceridemic at the time of
inclusion, and 30 (65.2%) of them also were hyperc-
holesterolemic.
All 46 dogs completed the trial. No adverse effects
were reported by the owners, and there was no change
in body weight or body condition score during the
study.
The BZF dosage was 6.0  1.5 mg/kg (range, 4–
10 mg/kg). At the end of the trial, 42 dogs had normal
serum TG concentration (42/46 = 91.3%). Of the 30
dogs that were initially hypercholesterolemic, 20 had
normal serum CHO concentrations at the end of the
trial (66.7%). Serum TG concentrations in the 46 dogs
decreased significantly from median (range) of 487
(350–4356) mg/dL at T0 to 92 (41–443) mg/dL at T30
(P = .0001; Table 2; Fig 1). Compared to T0, TG was
decreased at T30 by a median (range) of 84% (68–
95%). There was a strong negative correlation between
TG at T0 and ΔTG (r = 0.995, P < .0001; Fig 2).
There was also a significant decrease in serum CHO
from 352 (125–973) mg/dL to 238 (131–491) mg/dL
after treatment (median decrease 32% [ranging from an
increase of 24% to a maximum decrease of 73%,
P = .0001; Fig 3). Baseline CHO concentration was
negatively correlated to ΔCHO (r = 0.95, P < .0001;
Fig 4). In dogs that were hypercholesterolemic at T0
(n = 30), CHO decreased at T30 by 45% (13–73%,
P = .001), and in 66% of them, CHO concentrations
were <300 mg/dL. Of the 16 dogs that had normal
CHO at T0, CHO decreased significantly (P = .01) from
baseline but still remained in the normal range at T30,
with a median decrease of 12% (ranging from a 24%
increase to a 41% decrease). Five of these dogs had
an increase in CHO at T30 (range at T30, 155–260
mg/dL).
Comparing primary and secondary hyperlipidemia
groups, there was no difference in baseline CHO
(P = .7) or baseline TG (P = .1). However, ΔTG was
higher in the primary group (median [range] = 616
[307 to 4059] mg/dL) vs. the secondary group (379
[288 to 1533] mg/dL, P = .046). In contrast, there
was no difference in ΔCHO between primary and sec-
ondary groups (P = .4).
There was a significant decrease in ALT activity
(P = .01) in the group as a whole (Fig 5). In the sec-
ondary hyperlipidemia subgroup, ALT activity
decreased significantly (P = .001), but in the primary
hyperlipidemia subgroup, the decrease in ALT was not
Table 2. Serum concentrations of triglycerides (mg/
dL), cholesterol (mg/dL), ALT activity (U/L), and CK
activity (U/L) before (T0) and after 30 days (T30) use
of bezafibrate.
T0 T30 P value
TG
Mean  SD 752  663 110  82 .0001
Median (Range) 487 (350–4,356) 91.5 (41–443)
CHO
Mean  SD 428  217 244  72 .0001
Median (Range) 352 (125–973) 238 (131–491)
ALT
Mean  SD 128  96 100  56 .01
Median (Range) 87 (14–422) 93 (14–312)
CK
Mean  SD 105  32 111  42 .34
Median (Range) 95 (57–178) 107 (57–274)
CK, creatine kinase; CHO, cholesterol; ALT, alanine amino-
transferase transaminase; TG, triglycerides; SD, standard
deviation.
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Fig 1. Box-and-whiskers graph of serum concentrations of
triglycerides (TG), before (T0) and 30 days after (T30) therapy
with bezafibrate in 15 dogs with primary hyperlipidemia (1o) and
31 dogs with secondary hyperlipidemia (2o). Boxes represent 25th
and 75th percentiles with median in between. The whiskers repre-
sent values at 1.59 IQR (interquartile range) and the individual
points represent outliers.
Fig 2. Correlation between TG at T0 and the change in TG from
T0 to T30.
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significant (P = .07). There was no significant difference
in ΔALT between the subgroups (P = .8). There was no
change in CK activity (P = .3) in the group as a whole
or in the 2 subgroups (data not shown).
Discussion
Treatment options for hyperlipidemia in dog are lim-
ited. We evaluated the effect of BZF in a large group of
hyperlipidemic dogs. Normalization of serum TG con-
centrations (≤150 mg/dL) was observed in 91.3% of
dogs, with a median decrease of 84% within 1 month.
This a larger effect than observed in people (based on
meta-analysis) in which serum TG decreased by 14–
38%.27 The study population in people, however, was
mostly composed of patients with cardiovascular dis-
ease, with a minority of type 2 diabetics. The goal of
fibrates in these cardiovascular patients was not to
decrease their TG concentration, but to decrease their
total CHO concentration and increase their HDL
concentration. Indeed, in these studies, BZF led to a
26–52% increase in HDL.27
Hypercholesterolemia was not the main target of
treatment in our study, but it also resolved in the
majority of dogs (66%, n = 20/30). Cholesterol concen-
trations decreased even in dogs that started the study
with normal CHO. Our study cannot determine whether
this observation is a result of improvement in TG or an
independent effect. With these results, however, and
considering the mechanism of action of fibrates, it
seems reasonable to also study the effect of BZF in
dogs that are hypercholesterolemic but not hypertriglyc-
eridemic. Fibrates alter free fatty acid (FFA) metabo-
lism by activating PPAR, especially PPARa.24 As a
result, fibrates augment the oxidation of FFA in the
liver and divert them from TG synthesis, which leads to
decrease in synthesis of VLDL. Peripherally, fibrates
increase the expression of the LPL gene, with conse-
quent increase in HDL production and stimulation of
reverse CHO transport.23,24
The use of lipid-lowering drugs in general, and
fibrates in particular, has seldom been reported in dogs.
Gemfibrozilf was one of the first fibrates to be used in
dogs with hypertriglyceridemia (10 mg/kg q12h PO),
but there are no studies evaluating the efficacy and
safety of gemfibrozil in dogs. Anecdotally, gemfibrozil
in dogs has been associated with various adverse effects
(e.g, vomiting, diarrhea, decreased appetite). Moreover,
clinical experience suggests that the lipid-lowering effect
of gemfibrozil is insufficient in some dogs with primary
hyperlipidemia.1,11 In people, gemfibrozil is less effica-
cious than BZF and 15.8% of patients discontinue
using it because of gastrointestinal adverse effects.28 To
date, there are no reported studies in dogs comparing
the use of different lipid-lowering drugs, and only a few
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Fig 3. Box-and-whiskers graph of serum concentrations of
cholesterol (CHO), before (T0) and 30 days after (T30) therapy
with bezafibrate in 15 dogs with primary hyperlipidemia (1st) and
31 dogs with secondary hyperlipidemia (2nd). Boxes represent 25th
and 75th percentiles with median in between. The whiskers repre-
sent values at 1.59 IQR (interquartile range) and the individual
points represent outliers.
Fig 4. Correlation between CHO at T0 and the change in CHO
from T0 to T30.
Fig 5. Box-and-whiskers graph of serum ALT activity before
(T0) and 30 days after (T30) therapy with Bezafibrate in 15 dogs
with primary hyperlipidemia (1o) and 31 dogs with secondary
hyperlipidemia (2o). Boxes represent 25th and 75th percentiles with
median in between. The whiskers represent values at 1.59 IQR
(interquartile range) and the individual points represent outliers.
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isolated reports on fenofibrate and BZF.11,29,c In experi-
mentally induced hyperlipidemia, fenofibrate (10 mg/kg
PO immediately after feeding) was associated with a sig-
nificant decrease in TG and CHO in 6 obese beagles.
Dogs with higher baseline lipid concentrations had the
largest responses,30 as observed in our study with the
use of BZF.
In people, BZF is administered every 8 or 12 hours,
with food.24 The use of BZF for treatment of hyperlipi-
demia in dogs was first reported in 2003 in 2 Miniature
Schnauzers that were not responsive to dietary therapy.g
In these 2 cases, BZF administered at a dosage of
2.5 mg/kg q12h was associated with marked decrease in
TG (from 891 mg/dL and 4,398 mg/dL pretreatment to
306 mg/dL and 419 mg/dL after treatment, respec-
tively). We used a higher dosage and once daily admin-
istration because BZF was only available commercially
as a 200 mg tableth and we wanted to avoid scoring of
tablets inaccurately or compounding the drug. Appar-
ently, this more convenient regimen still is effective and
nontoxic.
Adverse effects most frequently associated with the
use of fibrates in humans are muscle pain, emesis, diar-
rhea, increased CK and ALT activity, and increased
risk of biliary calculi. Fibrates therefore are contraindi-
cated in patients with renal dysfunction and in those
with liver and gallbladder diseases.24,25 None of these
adverse effects, however, were observed in our study.
Moreover, ALT activity decreased in dogs that first pre-
sented with increased ALT activity. This improvement
in ALT is likely related to a decrease in circulating TG
concentrations and improvement of hepatic
lipidosis.23,24 Contrary to what is observed in people,
myopathy secondary to fibrate therapy seems infrequent
in dogs.29 We found no clinical signs associated with
myopathy and no increase in CK activity in our study.
Importantly, the lack of adverse effects (and indeed,
even the improvement in ALT activity) should be inter-
preted with caution, considering the relatively short
duration of this study. Regardless of the underlying dis-
ease that is causing hyperlipidemia, most dogs that were
in need of BZF therapy most likely would need lifelong
therapy for their hyperlipidemia. Therefore, the safety
and efficacy of BZF should be further evaluated in
long-term clinical trials before final conclusions are
drawn regarding its use.
One limitation of our study was lack of uniform
screening for causes of secondary hyperlipidemia.
Screening tests were done at the discretion of the
attending clinician. As such, cases of secondary hyper-
lipidemia might have been categorized incorrectly as
primary. Doing so could have obscured differences in
response to treatment, but even so, the magnitude of
decrease in hypertriglyceridemia was higher in cases of
primary vs. secondary hyperlipidemia. This finding
could be explained by the fact that in secondary
dyslipidemias, hormonal influence contributes a more
negative impact on the genesis of hyperlipidemia. In
hypercortisolism (naturally occurring and iatrogenic) in
dogs, for example, about 75% of patients are
hypercholesterolemic, hypertriglyceridemic, or both
because of the stimulation of lipolysis of visceral fat
by glucocorticoids, increased activity of hormone-sensi-
tive lipase and impaired removal of plasma TG due to
inhibition of lipoprotein lipase.2,3 Similarly, about 80%
of dogs with hypothyroidism are hyperlipidemic.30 This
hyperlipidemia is caused by a decrease in the lipid
degradation rate and increased lipid synthesis,
decreased biliary excretion of CHO, and a decrease in
the activity of lipoprotein lipase, leading to the accu-
mulation of HDL, LDL, and VLDL.11,30 The differ-
ence in magnitude of decrease between groups also
could be related to progression of the underlying dis-
ease in the secondary hyperlipidemia group. The
underlying disease was not treated during the 30 days
of the study, which could have offset the benefit of
BZF treatment.
In primary hyperlipidemia cases, or in cases of sec-
ondary hyperlipidemia that fail to completely respond
to treatment of the underlying disease, dietary fat
restriction usually is the next line of treatment in
hyperlipidemic dogs. In those cases in which dietary
fat restriction is ineffective, lipid-lowering drugs are
indicated, especially with the advent of safe and effec-
tive drugs.11,22 Based on the results of our study, we
conclude that once daily BZF at a dosage of 4–10 mg/
kg is effective in controlling hypertriglyceridemia and
hypercholesterolemia in dogs with primary and sec-
ondary dyslipidemia. No clinical adverse effects were
observed in our study as well as no increases in CK
and ALT activity during the treatment period.
Long-term evaluation of BZF therapy in dogs with
hyperlipidemia is necessary to determine its safety and
efficacy not only in decreasing serum lipid
concentrations in the blood but also in preventing the
complications of hyperlipidemia.
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